Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE
Authors' conclusion
We found no additional risk factors of cancer for RA patients under TCZ, beyond those already known in the general population.
Study context
- Population
- Rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ), French registry REGATE, 2011–2016
- Participants
- 1,496 patients3990.9 patient-years
- Outcome
- Incidence and risk factors of cancer
- Follow-up
- Five years
Methodological detailsnational registry, multivariate Cox proportional hazards models, Mean TCZ duration 32.0 (±22.0) months; mean follow-up 47 (±15.2) months
- National registry
- Multivariate Cox proportional hazards models
- Mean TCZ duration 32.0 (±22.0) months; mean follow-up 47 (±15.2) months
Main finding
As reported in the abstract
- Patients diagnosed with cancer during follow-up
- 63 (4.2%)
- Total cancers
- 75
- Cancers by type: solid neoplasms / hematological malignancies / melanomas / non-melanoma skin cancers (NMSC)
- 35 / 11 / 3 / 26
- Overall incidence of cancer excluding NMSC
- 7.5/1000 patient-years (PY)
- High age, risk factor for solid cancers (multivariate), HR
- 1.05 [1.02-1.08]
- Current smoker, risk factor for solid cancers (multivariate), HR
- 2.65 [1.27-5.53]
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE. Joint Bone Spine. Published 4 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →